Saturday, December 6, 2025
12:15 p.m. – 12:45 p.m.
ASH ANNUAL MEETING
Orange County Convention Center, Booth #971
Orlando, FL
PRESENTING FACULTY
 |
Matthew Matasar, MD, MS Chief, Blood Disorders Rutgers Cancer Institute New Brunswick, NJ |
PROGRAM OVERVIEW
This innovative educational experience is designed for hematologists/oncologists and their clinical teams involved in the treatment of patients with B-cell Non-Hodgkin lymphomas (B-NHLs).
TARGET AUDIENCE
This activity is designed to meet the educational needs of clinicians involved in the evaluation and management of patients with RRMM and B-NHLs including, but not limited to, hematologists, hematologist/oncologists, oncologists, primary care physicians (PCPs), and advanced practice providers (APPs; e.g., nurse practitioners, oncology nurses, pharmacists, and physician assistants).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Employ best practices for Readily identify AEs associated with bispecific antibody treatment for B-NHLs and utilize best practices in AE management for patients with R/R B-NHLs
- Explain current clinical trial data informing the use of bispecific antibodies in the management of R/R B-NHLs
- Readily identify AEs associated with bispecific antibody treatment for B-NHLs and utilize best practices in AE management for patients with R/R B-NHLs B-NHL screening to facilitate prompt and accurate diagnosis
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
